Mounjaro vs Zepbound: Same Tirzepatide, Two Labels, and What That Means for You

If you are comparing Mounjaro vs Zepbound, you have probably noticed that friends, ads and news stories use the two names almost as if they were one. There is a reason for that: the medicine inside is the same. What differs is who each brand is approved for, how the dose is chosen, and which trials stand behind each label. This guide walks through those differences in plain language, using the two U.S. prescribing labels and the FDA’s own drug database. For the bigger question of how tirzepatide compares with semaglutide, see our semaglutide vs. tirzepatide comparison.

Is Mounjaro the same as Zepbound?

In one important way, yes. Both labels list the same active ingredient, tirzepatide, from the same company, Eli Lilly. Both describe it the same way: a medicine that acts on two gut hormone receptors, GIP and GLP-1. Both come in the same six single-dose strengths, from 2.5 mg to 15 mg, taken once a week as a shot under the skin. And both carry the same boxed warning about thyroid C-cell tumors.

In another way, no. A brand name is tied to a specific FDA approval, and these two were approved for different jobs. Mounjaro was approved in May 2022 to improve blood sugar control in type 2 diabetes. Zepbound was approved in November 2023 to help adults lose excess weight and keep it off long term. In December 2024, Zepbound added a second use: moderate to severe obstructive sleep apnea in adults with obesity. Because the uses differ, so do the dosing goals, the trials behind each label, and who each one is meant for.

Mounjaro vs Zepbound at a glance

The pattern is easy to see. Nearly every row about the medicine itself says “both.” The rows that differ are about the approval: the condition being treated, the age group, and the evidence each label is built on.

What is the generic name for tirzepatide?

Tirzepatide is the generic name. It is the official, nonbrand name of the active ingredient, and it appears in parentheses after the brand on both labels: Mounjaro (tirzepatide) and Zepbound (tirzepatide). Doctors, pharmacists and researchers use the generic name because it stays the same no matter which brand or package you are talking about.

Semaglutide follows the same pattern. Novo Nordisk sells it as Ozempic for type 2 diabetes and as Wegovy for weight management, and our Wegovy vs. Ozempic guide covers that pair. All four brands belong to the family of medicines explained in what GLP-1 is and how these medicines work.

Is there a generic version of Mounjaro or Zepbound?

Not today. As of October 2026, the FDA’s Drugs@FDA database lists tirzepatide under only two applications, both held by Eli Lilly: one for Mounjaro and one for Zepbound. Neither shows a generic equivalent. So when people say “generic tirzepatide,” the word generic only describes the ingredient’s name. The FDA has not approved a generic copy of either brand.

Tirzepatide brand names, and why one medicine has two

In the United States, tirzepatide has two brand names: Mounjaro and Zepbound. The FDA database also lists pen versions under each name, such as an autoinjector and a KwikPen, but those are ways of packaging the dose, not separate medicines.

The two names track two separate FDA applications. Each one has its own trials and its own approved uses. Mounjaro’s label rests on trials in people with type 2 diabetes: most measured blood sugar control, and one large trial measured heart attacks, strokes and heart-related deaths. Zepbound’s label rests on weight-loss trials, and later on sleep apnea trials. That is also why the two labels read differently even though the drug is the same.

Mounjaro vs Zepbound for weight loss: does the brand change your results?

No. The medicine is the same, so the name on the box is not what drives results. What the trials do show is that the person matters: the dose they reach, how well they tolerate it, and whether they have type 2 diabetes.

Zepbound’s label reports two 72-week trials. Everyone in them also got diet and activity counseling. Here is the average change in body weight:

Two things stand out. Higher doses led to more weight loss on average. And in these two separate trials, people with type 2 diabetes lost less on the same doses than people without it. That is a difference between groups of people, not between brands.

Mounjaro’s label measures something else. Its trials were built mainly to track blood sugar control and heart events, though they also recorded body weight. The label notes that tirzepatide decreases food intake and reduces body weight in people with type 2 diabetes. So when someone with diabetes loses weight on Mounjaro, they are getting the same medicine’s effect. The label simply was not written with weight as the goal.

Trial numbers are averages, not promises. Your own result depends on your dose, your eating and activity, your sleep and your health. For a realistic month-by-month picture, see our GLP-1 weight loss timeline.

Same dose steps, different goals for each step

Both labels start at 2.5 mg once a week and raise the dose in 2.5 mg steps, at least four weeks apart, up to 15 mg. The slow climb is there to limit stomach side effects. What differs is the reason for each step.

• Mounjaro: the dose goes up if more blood sugar control is needed. The top dose is 15 mg a week for adults and 10 mg for children 10 and older.
• Zepbound: 2.5 mg is a starting dose only, not a long-term one. For weight, the maintenance dose is 5, 10 or 15 mg a week, chosen by response and tolerance. For sleep apnea, it is 10 or 15 mg.

Because the strengths match, people often ask whether a Mounjaro dose “equals” the same Zepbound dose. The ingredient and the milligrams are the same. But which dose is right for you, and when to change it, is a prescriber’s decision based on your goal and how you are doing.

Side effects and warnings are shared

Since both brands contain tirzepatide, their safety sections overlap heavily. The most common side effects on both labels are digestive: nausea, diarrhea, vomiting, constipation, indigestion and stomach pain. Mounjaro’s list also includes a smaller appetite. Zepbound’s list, drawn from weight-loss trials, adds injection site reactions, fatigue, allergic-type reactions, burping, hair loss and reflux.

The serious warnings match too. Both labels carry the boxed warning about thyroid C-cell tumors seen in rats. Both caution about pancreatitis, gallbladder problems, kidney injury from dehydration, severe stomach side effects, low blood sugar when combined with insulin or a sulfonylurea, and the risk of inhaling stomach contents during anesthesia or deep sedation. Neither is used by people with a personal or family history of medullary thyroid cancer or MEN 2. Both also say birth control pills may work less well for four weeks after starting and after each dose increase.

Our guide to tirzepatide side effects explains what each one tends to feel like, how long it lasts, and when to call your doctor.

Can you switch between Mounjaro and Zepbound, or take both?

You should not take them together. Zepbound’s label says it contains tirzepatide and should not be combined with other tirzepatide products or with any GLP-1 medicine. Taking both would mean taking tirzepatide twice.

Changing from one brand to the other is a different question. People ask about it when a diagnosis changes, or when the goal of treatment shifts from blood sugar to weight. The labels do not give a brand-to-brand switching schedule, so the timing and the dose are your prescriber’s call. They will look at your current dose, the date of your last shot, and how you have felt on it. If you are coming from semaglutide instead, our guide to switching from semaglutide to tirzepatide explains how that change is usually handled.

How MeliOra fits: tirzepatide care with a physician who comes to you

MeliOra Elite Wellness is a physician-led practice based in Lutz. Dr. Melanie Espinet, a board-certified family physician, prescribes semaglutide or tirzepatide when it is right for you, and she explains your specific medication at your visit. She reviews your health history, your medicines and your labs, then sets your dose and adjusts it herself at your check-ins.

Tirzepatide at MeliOra is $230/month at starting doses and $320/month for higher dosing. That monthly price includes physician visits, lab work, your medication and supplies, and dose adjustments and check-ins, with no separate consultation fee. Dr. Espinet makes house calls across Tampa Bay with no travel fee, sees select patients at the Lutz office, and offers video visits for weight loss to patients anywhere in Florida at the same monthly price. See tirzepatide weight loss in Lutz and Tampa for how the plan works.

Weight-loss medicines are generally considered for adults with a BMI of 30 or higher, or 27 or higher with a weight-related problem such as high blood pressure or type 2 diabetes. They are not right for everyone with a high BMI, and Dr. Espinet will tell you honestly if tirzepatide is not a good fit. If you already take Mounjaro or Zepbound from another prescriber, bring the name, your dose and the date of your last shot to your first visit.

Related Services

• Tirzepatide Weight Loss in Lutz & Tampa
• Medical Weight Loss in Lutz, FL
• Semaglutide vs. Tirzepatide
• Zepbound vs Wegovy
• Tirzepatide Side Effects

Sources & References

• Mounjaro (tirzepatide) injection, U.S. Prescribing Information, Eli Lilly, revised 08/2026
• Zepbound (tirzepatide) injection, U.S. Prescribing Information, Eli Lilly, revised 08/2026
• Drugs@FDA: Mounjaro, NDA 215866 (approval history and therapeutic equivalents), U.S. Food and Drug Administration
• Drugs@FDA: Zepbound, NDA 217806 (approval history and therapeutic equivalents), U.S. Food and Drug Administration
• Prescription Medications to Treat Overweight & Obesity, National Institute of Diabetes and Digestive and Kidney Diseases (NIH)